How understudied populations have contributed to our understanding of Alzheimer’s disease genetics

Nadia Dehghani¹, Jose Bras¹,², Rita Guerreiro¹,²,*

¹ Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, Michigan, USA
² Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids, MI, USA

*Corresponding author
Rita Guerreiro
Center for Neurodegenerative Science, Van Andel Institute, 333 Bostwick Ave. N.E., Grand Rapids, Michigan 49503-2518 USA
Email: Rita.Guerreiro@vai.org

Abstract

The majority of genome-wide association studies have been conducted using samples with a European genetic background. As a field, we acknowledge this limitation and the need to increase the diversity of populations studied. A major challenge when designing and conducting such studies is to assimilate large samples sizes so that we attain enough statistical power to detect variants associated with disease, particularly when trying to identify variants with low and rare minor allele frequencies. In this study, we aimed to illustrate the benefits, to genetic characterization of Alzheimer’s disease (AD), in researching currently understudied populations. This is important for both fair representation of world populations and the translatability of findings. To that end, we have conducted a literature search to understand the contributions of studies, on different populations, to AD genetics. We systematically quantified the number of studies identifying mutations in known disease-causing genes, in a world-wide manner, and discussed the contributions of research in understudied populations to the identification of novel genetic factors in this disease. Additionally, we compared the effects of genome-wide significant SNPs across populations by focusing on loci that show different association profiles between populations (a key example being APOE). This work functions to both highlight how understudied populations have furthered our understanding of AD genetics, and to help us gage our progress in understanding the genetic architecture of this disease in all populations.

Keywords: Alzheimer’s disease, genetics, understudied populations, diversity

Introduction

The purpose of this review is to highlight key findings on the genetics of Alzheimer’s disease (AD) from studies performed on understudied populations. We define such populations in two distinct ways: as countries where there have been few reported variants when discussing studies focused on specific genes, and as ethnicities with few studies or no representation to date in GWAS. APP, PSEN1 and PSEN2 are the three genes harboring pathogenic mutations typically causing early-onset AD (EOAD) (age-at-onset below 65 years) in an autosomal dominant manner. Five to ten percent of EOAD is due to mutations in these genes. Over thirty
loci have been significantly associated with risk for late-onset AD (LOAD) including, ABCA7, BIN1, CLU, CR1, SORL1 and APOE. The E4 allele of APOE is currently the strongest genetic risk factor for LOAD. The heritability of AD is estimated to be 79% with this being higher for EOAD, however, the SNP heritability of LOAD (defined as the phenotypic variance attributable to common variants), is predicted to be approximately 31%. This suggests that a large proportion of AD heritability is still to be identified and could be due to rare variants.

Approximately 78% of all genetic studies from the NHGRI-EBI GWAS Catalog have been conducted on individuals of European origin. To note, the labels “European,” “non-Hispanic white” and “Caucasian” are commonly used interchangeably in the literature. In this review, we refer to these populations as described in the papers referenced and use the term non-Hispanic white (NHW) to broadly refer to both Americans and Europeans. Not only are there few studies on other populations, but many variants identified by large genetic studies on NHWs have not been replicated in other populations. This may be derived from lower sample sizes used in the replication experiments, or it may suggest that AD has a different genetic architecture, and perhaps even different mechanism(s) of disease in different populations. Although, it has been suggested that the same molecular pathways are disrupted in AD across populations, differences may occur in the genes involved and the specific impinging points in these pathways. Studying different populations is, thus, critical to our better understanding of the genetics of AD. This review aims to highlight our progress in studying AD across the world by discussing the key findings from such studies and corroborating insights and best practices to lead us throughout the next phase of human AD genetic studies.

AD Mendelian genetics around the World

We first conducted a thorough literature search on 26th October 2019 by programmatically searching PubMed for the following terms: "Alzheimer* AND (PS1 OR PS2 OR PSEN1 OR APP OR PSEN2 OR presenilin OR amyloid precursor protein OR S182 OR E5-1) AND (mutation* or variant*) AND " + country name. In order to interpret the 7,781 results, we filtered our results based on the metrics shown in Figure 1.
pathogenic. Grey depicts countries with no studies on patients reporting variants in APP, PSEN1 or PSEN2. The number of studies reported ranges from 1 study in countries depicted in yellow (Brazil, Cuba, Hungary, Israel, Peru, Serbia, Czech Republic, South Africa, Uruguay, Slovenia, Ireland, Slovakia, Taiwan and India) to 46 studies reported in Italy depicted in black, closely followed by 43 studies in Japan and 33 studies in China. References are in supplementary table 1.

Figure 3. APP, PSEN1 and PSEN2 variants reported in patients from each country or population. Variants included are the risk modifier PSEN1:p.Glu318Gly and missense and indels reported in AD cases as potentially pathogenic. We can clearly see that variants in PSEN1 are the most common, with patients from the majority of countries reporting between 1-15 unique variants in this gene. No reports were found describing PSEN1 variants in patients from Hungary or Taiwan, which is unusual given that pathogenic variants in this gene are the most frequent Mendelian cause of AD. This may be accounted for by the fact that, if patient country was not specifically reported, then study was not included. Patients from China, France, Italy, Japan, Korea, Spain, UK and US report over this range. Morocco stands out as having patients with more reports of APP variants compared to PSEN1 variants; these are all frameshift variants and may not have been reported in other studies if they focused on missense, although, we can see from gnomAD that indels in APP are rare. In addition to patients from specific countries, there are also single-study reports of variants in patients from distinct populations (North American Aboriginal Kindred, Ashkenazi Jewish, African American and Caribbean Hispanic) which have also been included since these are distinct populations which encompass different countries. References are in supplementary table 1.

France is the country with the most variants reported, followed by China. When crossing the data derived from Figure 2 with that of Figure 3, it is clear that there are many more studies reporting few or individual variants in Chinese cohorts, as opposed to a small number of large studies in France reporting many variants. Many of the variants in the publications originating in China are novel and not replications of previous findings. Out of a total of 63 variants reported in China, 34 of these are unique to China since they have not been reported in any other countries to date (see supplementary table 2). It is interesting to note that the South of Europe has a considerable number of studies originating from Spain and Italy, but that Portugal is an understudied population for AD genetics. This is an important fact that can be missed if this population is combined with the Spanish and broadly referred to as Iberian.

In Colombia, two reported variants include: the PSEN1:p.Ile416Thr, which originated on an African haplotype 5, and the widely reported PSEN1:p.Glu280Ala, which segregates in a large community of over 5,000 people from Medellín, Colombia 6. In this understudied, yet highly informative population, it has been shown that elevated levels of tau deposition measured by PET imaging precede clinical onset of AD by approximately 6 years. This is important, since the ability to identify at-risk individuals prior to any symptom onset could be used to develop improved clinical trial designs for new therapies for AD. Accordingly, there is an ongoing phase II clinical trial (NCT01998841), involving presymptomatic carriers of the PSEN1:p.Glu280Ala, which tests the drug Crenzumab to target amyloid beta plaques. Even in such a unique population, composed of a very large number of individuals with the same mutation, and thus, very predictable disease course, positive results from this clinical trial could potentially impact
patients across the whole world. In addition to the unique ability to develop genetically informed clinical trials in this extended family, the finding of the same mutation in such a large number of individuals also enables for the study of genetic modifiers of the disease. Recently it was found that the E2 allele of APOE delays the age at onset (AAO) of disease in cases carrying the PSEN1:p.Glu280Ala mutation⁷, and the DAOA:p.Arg30Lys variant was found to be significantly associated (P=1.94×10⁻⁶) with AAO⁸. More recently, one individual from this kindred demonstrated high resilience to AD with a delay of over 30 years on their AAO of MCI, despite high amyloid beta plaque load and carrying the PSEN1:p.Glu280Ala. They were identified as homozygous for the rare APOE E3 Christchurch variant p.Arg136Ser (equivalent to APOE:p.Arg154Ser)⁹.

Additional reports suggest that the PSEN1 Glu280 residue is important in normal protein function for many populations. At the same protein residue, there is a report of another variant, PSEN1:p.Glu280Lys, in three siblings with EOAD from a Malaysian family¹⁰. Ten additional family members (6 with neuropsychiatric symptoms and 4 asymptomatic) were screened and were negative for this variant, suggesting segregation with the disease in that family. Two additional PSEN1 variants in apparent NHWs, PSEN1:p.Glu280Gly¹¹ and PSEN1:p.Glu280Gln¹², have also been reported in AD cases.

With about 65% protein sequence similarity to PSEN1, the highly homologous PSEN2 gene also harbors mutations that cause EOAD. These two proteins are components of the gamma-secretase complex, which cleaves APP, and in addition to sequence, also share high structural similarity. Despite these similarities, mutations in PSEN2 are rarer (59 in PSEN1, 36 in PSEN2 per ClinVar assessed March 2020). The most common mutation in PSEN2 is the p.Asn141Ile, first discovered in the Volga Germans. Interestingly, it was noted that seizures were reported in about 1/3 of Volga German cases with this PSEN2 variant¹³,¹⁴. This is intriguing and, in a similar way to the work described in the Colombian kindred above, opens the possibility of using the Volga population to identify genetic modifiers of AD that could be responsible for the seizures in this population. The cohort of 146 affected cases from 11 Volga German families, with seizures reported in 20 out of 64 of these cases, is a useful resource for such genotype-phenotype associations¹⁵. Detecting if a patient is susceptible to developing seizures is important for close monitoring and prescription of medications.

Although there are no reports of variants in APP, PSEN1 and PSEN2 causing AD in Iceland, there is one report of an APP:p.Ala673Thr variant as protective against AD and cognitive decline in an elderly Icelandic population¹⁶. This variant has since been identified in a Finnish individual who lived to 104.8 years¹⁷. There are also reports of North Americans with this variant; some of whom are unaffected or have LOAD¹⁸. All but one (who has Russian ancestry) of these reported individuals have broadly Scandinavian ancestry. To note, the frequency of this variant is much lower in populations outside Iceland and Finland, therefore, this protective variant would not have been identified without extremely large cohorts. These findings clearly exemplify the benefit of studying isolated and/or genetically distinct populations. The reduced genetic heterogeneity within such cohorts allows for the comparison of low-frequency variants between cases and controls; much larger sample sizes in populations with higher degrees of heterogeneity are required for sufficient detection power. It is interesting to note that at the same amino acid position in APP, there is one example of a recessive variant (APP:p.Ala673Val) which has been identified in two Italian siblings, one with early-onset dementia and the other with MCI; family members heterozygous for this variant were reported as unaffected¹⁹.

The absence of pathogenic mutations in the three known AD genes in a given population can suggest different possibilities: 1) the absence of genetic testing in that population; 2) the possibility of other causative genes underlying the disease in that population; and/or 3) the presence of rare high risk genetic variants altering the susceptibility of individuals to AD in the population.

In conclusion, one can extrapolate if a population has been studied for AD genetics by searching for reports of variants in the genes known to harbor pathogenic variants that are implicated in Mendelian-inheritance of AD. The prediction of mutational damage to human genes should include population-specific analyses, as the predictions from current tools likely vary depending on ethnic background and the demographic history of the
From our analysis, it is clear that there is wide variability not only in the number of studies across the globe, but also in the number of variants identified in each country. This has implications for future studies in the genetics of AD at a global level as it identifies populations to whom resources should be provided so that genetic studies can be performed. Even in the absence of effective therapies to prevent or delay AD, knowing the genetic status of an individual or family gives the opportunity for genetic counseling, informed preparation of life affairs (including reproductive options), and may contribute to achieve a more accurate in-life diagnosis.

**AD genetic risk in different populations**

**Representation of other populations in GWAS**

We can use a similar approach to what was described in the previous section to determine which populations are lagging in terms of identifying common genetic variability associated with AD. To this end, and to explore the representation of different populations in AD GWAS, we used information from all available studies, with corresponding ancestry data, from the NHGRI-EBI GWAS catalog (16th January 2020 release). After filtering the studies for those focusing on AD, we identified 76 studies. In these, there was a clear overrepresentation of cohorts defined as broadly European (Figure 4). It is indisputable that large-scale genetic studies have revolutionized our understanding of the genetics of AD, however, this overrepresentation clearly highlights the need to study other populations in order for new genetic risk factors to be identified. To also emphasize this for diseases in general, the NHGRI-EBI GWAS catalog has released the GWAS Diversity Monitor which allows quasi-real-time monitoring of ancestries represented in GWAS studies.

**Translatability of known AD GWAS hits to date**

In an attempt to compare the effect sizes of GWAS findings in NHW cohorts with other populations, we present ORs for the lead SNPs identified in the two most recent AD GWAS, which have also been tested in other populations (Table 1). We used the results presented by Kunkle et al. and Jansen et al. to represent NHW cohorts and searched the NHGRI-EBI GWAS catalog for studies of those same SNPs in other populations. We recorded 1) ORs from genome-wide significant SNPs and 2) ORs for variants in the same locus as these, from other populations (these variants did not have to reach genome-wide significance (GWS) to be recorded). In most cases, only the OR from the NHW data reached GWS, however there is one notable exception in APOE. The APOE E4 haplotype is the strongest genetic risk factor for LOAD and its dose-dependent effects were first discovered in 1993. It was subsequently found that the APOE E2 isoform is protective against AD. The large increase in risk of LOAD conferred by the E4 allele in NHWs is not observed in the African American (AA) population where the risk conferred by this allele is smaller. This disparity has also been described in studies analyzing molecular biomarkers such as CSF total and phosphorylated tau in APOE E4-positive AAs AD.
Many studies report *APOE* allele frequencies (AFs) in different populations and, compared to Europeans, both Africans and Oceanians have higher *APOE* E4 AFs, with Asians having the lowest AF. The decreased risk observed with *APOE* E4 in AAs is due to local genomic African ancestry, with an estimated OR=2.34, as opposed to AAs with local genomic European ancestry in which the OR is estimated to be 3.05. A similar situation has also been shown in Puerto-Ricans (OR= 1.26 on African background, OR=4.49 on European background) and may suggest that the Caribbean Hispanic GWAS AD cases have a stronger African background accounting for their lower OR when compared to other populations in Table 1. *APOE* E4 carrier frequency in South America/Mexico (57.3%) is reported to be similar to that of USA/Canada (55.8%) . This extends our understanding from *APOE* E4 or E2 in conferring risk or protection, respectively, to appreciating how population genetic background, and even ancestry local to the *APOE* locus, as defined by Rajabli et al., can modify such effects.

Although based on a small sample size, the data suggests that both *CR1* and *FERMT2* have an opposite direction of effect in Israeli-Arabs. It should be noted that, due to the sample size, there are very large confidence intervals associated with these ORs. Despite not always reaching GWS, the *CLU* rs9331896-C is associated with lower risk of AD in most populations, with the exception, with an OR close to 1, of African Americans. In line with this finding, Tycko et al., failed to identify any *CLU* polymorphisms associated with AD in African Americans. Moreover, a meta-analysis of 14 cohorts (total of 7,070 AD cases and 8,169 controls) concluded that rs11136000 in *CLU* is only associated with AD in NHWs (OR=0.91), and not in AA, Arab or Caribbean Hispanic populations. A study on a small South Indian cohort (243 cases and 164 controls) also reported no association between rs11136000 and AD, following genotyping of this polymorphism. In the Chinese population, conflicting reports describing meta-analyses have been published with some reporting a significant association between rs11136000 and LOAD, while others concluded that there was no effect. More recently, in a large meta-analysis including 24 individual studies, Almeida et al. showed rs11136000 to be protective; an association that remained statistically significant for the Caucasian as well as the mixed samples (from China, Japan, India, and Turkey). As expected, there were high levels of genetic heterogeneity in the mixed samples, highlighting the need to study associations in large enough cohorts of individual populations.

In the *BIN1* locus two SNPs have been reported with disparate associations in different populations, suggesting that independent signals exist in these populations (Table 1). The first, rs6733839, has been widely reported as a risk variant in various populations, however, in AAs there was no strong evidence of association. The second, rs744373, was identified as a risk variant in Japanese with no evidence for association in AA or Turkish populations. Following targeted sequencing and follow-up genotyping, Vardarajan et al., 2015 found *BIN1*:p.Lys358Arg (rs138047593) in 8 Caucasian and 6 Hispanic LOAD patients; segregation was shown in 2 out of 6 Caribbean Hispanic families. The authors reported higher frequency of this variant in familial cases (0.0859) where there was more than one affected individual in a family, compared to unaffected carriers (0.0084), and speculated that this increased *BIN1* rs138047593 frequency may be due to epistasis with other risk factors (genetic or environmental). Segregation was not tested in Caucasians because 7 out of 8 of them were from the Toronto LOAD study where there were no reported families. Although one Caucasian patient was from the NIA-LOAD study that includes families, segregation was not tested because the allele frequency of this variant for Caucasians in the ExAC database was similar to that observed in the LOAD cohort, suggesting that it was not associated with LOAD. Taken together these data show that *BIN1* variants have a similar effect in Asian and NHW populations, however, in AAs there was no strong evidence of association. The authors suggested that rs202178565 may play a stronger role in AD risk in the Caribbean Hispanic population, however, further studies in larger datasets are needed to confirm this hypothesis.
At the CNTNAP2 locus, Jansen et al found a significant signal for rs114360492. This locus was previously reported in both AAs as well as in Japanese, however, the direction of effect was opposite in these two populations (risk and protection, respectively); it should be noted that these associations did not reach GWAS in these populations. More recently, a GWAS in a Spanish cohort reported a significant association with rs117834366 near CNTNAP2 in a vascular dementia sub-cohort at the discovery stage; this had a very high OR of 6.03 (3.22-11.2). This finding indicated the possibility that the results observed by Jansen et al. could be due to the inclusion of vascular dementia cases in their AD cohort. However, the two variants show low frequency in the European population, which increases the likelihood of erroneous results due to low statistical power in smaller cohorts.

The ECHDC3 locus was recently reported in NHWs. Interestingly, prior to this finding, the same locus had been reported in a transethnic GWAS where rs7920721-G reached significance when samples from all populations (European ancestry, AAs, Israeli-Arabs and Japanese) were combined. The significance was lost when populations were analyzed separately, although the direction of effect was maintained. These findings show the power of using transethnic approaches to identify novel loci when the effects are concordant.

Table 1 shows that PICALM rs10792832-A presented a protective effect in all populations tested with a GWAS approach. In both South and East Asians, rs3851179 is in LD (R²>0.7) with rs10792832 which we report in Table 1. However, when looking at studies that tested the specific variant outside of a GWAS framework, discordant results were found regarding association of rs3851179 and AD in the Asian population. It is plausible that this may be related to pooling Chinese and Japanese populations together to increase sample size, with small differences in genetic background leading to less clear results. It is also possible that PICALM variants may not affect both populations equally, since a recent study on the Han Chinese population reported no association between variants in PICALM and LOAD. Finally, in a South Indian population, there was no association found between PICALM rs3851179 and AD using a small cohort of 243 AD patients and 164 age-matched healthy controls.

The ABCA7 locus is one of the strongest risk loci in AAs with rs115550680 showing an OR of 1.79 and reaching genome-wide significance. Although the authors mentioned that the SNP is in LD with the European risk variant (rs4147929), they have very different allele frequencies in both populations (leading to a high D' and low R²). This, again, emphasizes the distinct genetic backgrounds among populations that may lead to population-specific genetic architectures of disease. These must be taken into consideration, for example, when translating the finding of risk alleles for PRS in different populations. Whether ABCA7 plays a role in AD risk in the Asian is not clear with rs3764650 having been reported to be associated with AD in a Han Chinese population and no association between ABCA7 variants and AD being reported in two other studies on the same population.

A GWAS meta-analysis conducted using data from East Asian, North American and European populations (for a total of 31,106 cases and 55,653 controls) investigated the association of CD33 rs3865444 with AD susceptibility. The authors reported no significant association in the East Asian population (Chinese, Japanese and Korean), however, an OR of 1.7 (p=0.0036) was reported for the major allele rs3865444-C in the Chinese subgroup with lower heterogeneity compared with the entire East Asian cohort. This is in line with the protective effect conferred by rs3865444-A in NHWs and suggested in the Spanish, AAs and Caribbean Hispanics.

Many of the SNPs reaching significance in NHWs have been investigated in additional populations. When these are studied under a GWAS framework, the ORs in other populations usually do not reach significance, which is due, in all likelihood, to the smaller sample sizes being used. One example of this is the Israeli-Arab population where only 51 cases and 64 controls were used to calculate the ORs for the SNPs presented in Table 1. Given the clearly reduced statistical power in these smaller cohorts, results tend to focus on either a particular SNP or locus. This may account for the lack of ORs reported for Caribbean Hispanics in Table 1, compared to reports that we have mentioned. Nonetheless, key differences between populations can be observed for variants reaching significance, namely, the lower risk conferred by APOE in AAs, which is countered by the increased risk of ABCA7. A valuable tool in this space are transethnic GWAS, not only for...
comparison of ORs between populations, but also for aggregating enough samples to detect signals, which may then be replicated in other cohorts. The SNP near ECHDC3 is a good example, where a novel significant association was initially reported in a transethnic GWAS before being replicated in the most recent GWAS in NHWs. Importantly, although this study aggregated samples of multiple ancestries, they also present results for separate populations, which enables future studies in these populations to build upon these population-specific results. Two studies could not be included in this review because they combined NHW samples with those of Caribbean Hispanic ancestry and samples with Caucasian ancestry with AA samples. Lastly, it is important to note that post-GWAS analyses to investigate the potential effects of disease-associated SNPs are very informative and the field should gradually move its resources to systematically perform these for all nominated loci. The CELF1/SPI1 locus is a great example of this, where rs10838725-C had been previously associated with increased risk of AD in NHWs (OR 1.08) and recent work has shown that CELF1 rs1057233-G is associated with lower expression of SPI1 in monocytes and macrophages, and delayed AD onset. It is important to test such associations in cells with different ancestral backgrounds; both the National Centralized Repository for Alzheimer's Disease and Related Dementias and the Coriell Human Variation Panel may be a helpful resource with cell lines and DNA currently available from populations including African American, Middle Eastern, Italian and Greek.

Table 1. Odds ratios in different populations for GWAS hits that were significant in at least one population.

<table>
<thead>
<tr>
<th>CHR</th>
<th>Nearest gene</th>
<th>SNP-effect allele</th>
<th>NHW ORa (95%CI)</th>
<th>Spanish ORb (95%CI)</th>
<th>African American OR (95%CI)</th>
<th>Japanese ORd (95%CI)</th>
<th>Israeli-Arab OR (95%CI)</th>
<th>Caribbean Hispanic OR (95%CI)</th>
<th>Korean OR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CR1</td>
<td>rs6566401-A</td>
<td>1.17 (1.13-1.21)</td>
<td>1.10* (0.98-1.22)</td>
<td>1.23* (0.98-1.56)</td>
<td>1.38** (1.08-1.76)</td>
<td>0.65* (0.31-1.37)</td>
<td>K</td>
<td>1.24* (0.77-1.99)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs744373-G</td>
<td></td>
<td></td>
<td>1.25** (1.11-1.4)</td>
<td></td>
<td></td>
<td></td>
<td>0.98* (0.81-1.18)</td>
</tr>
<tr>
<td>2</td>
<td>BIN1</td>
<td>rs6738389-T</td>
<td>1.2 (1.17-1.13)</td>
<td>1.16* (1.07-1.27)</td>
<td>1.09* (0.99-1.21)</td>
<td></td>
<td>0.92* (0.54-1.57)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>INPP5D</td>
<td>rs10933431-G</td>
<td>0.91 (0.88-0.94)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs35349669-T</td>
<td>0.99* (0.91-1.07)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>HLA-DRB1</td>
<td>rs9271192-C</td>
<td>1 (0.90-1.10)</td>
<td>0.98* (0.89-1.08)</td>
<td>1.08* (0.93-1.27)</td>
<td>1.15* (0.59-2.24)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs9271058-A</td>
<td>1.1 (1.07-1.13)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>ZCWPW1</td>
<td>rs1476679-C</td>
<td>0.95* (0.87-1.04)</td>
<td>0.96* (0.81-1.15)</td>
<td>1.04* (0.89-1.22)</td>
<td>0.7* (0.42-1.17)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs12539172-T</td>
<td>0.92 (0.90-0.95)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NYAP1</td>
<td>rs11767557-C</td>
<td>0.9 (0.88-0.93)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EPHA1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>SNP</td>
<td>HWE p-value</td>
<td>OR (95% CI)</td>
<td>p-value</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------</td>
<td>-------------</td>
<td>-------------</td>
<td>---------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CNTNAP2</td>
<td>rs11771145-A</td>
<td>0.92* (0.85-1.01)</td>
<td>0.9* (0.82-1.00)</td>
<td>0.9* (0.77-1.05)</td>
<td>1.7* (0.98-2.94)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>rs114360492-T</td>
<td>1.20* (1.13-1.27)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>rs10273775-G</td>
<td>1.52* (1.27-1.84)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>rs117834366-A</td>
<td>2.08* (1.42-3.07)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>rs802571-C</td>
<td>0.52* (0.40-0.68)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTK2B</td>
<td>rs28834970-C</td>
<td>1.09* (1.00-1.19)</td>
<td>1.03* (0.93-1.14)</td>
<td>1.17* (0.98-1.40)</td>
<td>1.52* (0.90-2.58)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>rs73223431-T</td>
<td>1.1* (1.07-1.13)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CLU</td>
<td>rs9331896-C</td>
<td>0.88 (0.85-0.90)</td>
<td>1.04* (0.94-1.15)</td>
<td>0.87* (0.78-0.97)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>rs11136000-T</td>
<td>0.82** (0.77-0.99)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.79* (0.63-0.98)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECHDC3</td>
<td>rs7920721-G</td>
<td>1.08 (1.05-1.11)</td>
<td>0.99* (0.91-1.08)</td>
<td>1.09* (0.97-1.23)</td>
<td>1.17* (0.96-1.43)</td>
<td>1.30* (0.79-2.12)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PICALM</td>
<td>rs10792832-A</td>
<td>0.88 (0.86-0.90)</td>
<td>0.85** (0.68-1.07)</td>
<td>0.85* (0.73-0.89)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>rs3851179-T</td>
<td>0.96* (0.82-1.12)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MS4A</td>
<td>rs983392-G</td>
<td>0.86* (0.79-0.93)</td>
<td>0.85* (0.64-1.14)</td>
<td>0.9* (0.56-1.43)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>rs7933202-C</td>
<td>0.89 (0.87-0.92)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SORL1</td>
<td>rs11218343-C</td>
<td>0.8 (0.75-0.85)</td>
<td>0.97* (0.77-1.23)</td>
<td>1.01* (0.85-1.20)</td>
<td>0.83** (0.75-0.92)</td>
<td>0.85* (0.26-2.76)</td>
<td>0.96* (0.79-1.17)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FERMT2</td>
<td>rs17125944-C</td>
<td>1.19* (1.02-1.40)</td>
<td>1.06* (0.89-1.27)</td>
<td>1.04* (0.89-1.22)</td>
<td>0.32* (0.07-1.52)</td>
<td>1.22* (1.02-1.45)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>rs17125924-G</td>
<td>1.14 (1.09-1.18)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLC2A4/RIN3</td>
<td>rs10498633-T</td>
<td>0.99* (0.89-1.10)</td>
<td>1 (0.87-1.15)</td>
<td>0.95* (0.70-1.30)</td>
<td>0.7* (0.30-1.64)</td>
<td>0.88* (0.78-0.99)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>rs12881735-C</td>
<td>0.92 (0.89-0.94)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADAM10</td>
<td>rs593742-G</td>
<td>0.95* (0.87-1.05)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>rs442495-C</td>
<td>0.99* (0.98-0.99)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABCA7</td>
<td>rs4147929-A</td>
<td>1.11* (1.01-1.23)</td>
<td>1.22* (1.04-1.43)</td>
<td>1.68* (0.77-3.68)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
rs3752246-G & 1.15 (1.11-1.18) & 1.11 (1.08-1.15) & 1.79* (1.47-2.12) & \\
rs115550680-G & 1.03 (0.98-1.07) & 0.98 (0.95-1.02) & 1.00 (0.89-1.13) & \\
rs429358-C & 3.32 (3.2-3.45) & 2.92 (2.60-3.27) & 2.31* (2.19-2.42) & 1.89 (1.55-2.30) \\
rs394819-T & 0.99 (0.98-1.01) & 0.95* (0.90-1.01) & 0.70 (0.67-0.72) & \\
rs3865444-A & 0.99 (0.98-0.99) & 0.92* (0.84-1.01) & 1.04** (0.92-1.18) & 0.87* (0.79-0.96) \\
rs7274581-C & 1.29 (1.24-1.35) & 0.99* (0.86-1.13) & 1.15* (1.02-1.29) & 1.01* (0.53-1.93) \\
rs6024870-A & 0.88 (0.85-0.92) & 1.27 (1.08-1.50) & 1.17 (1.08-1.27) & 0.94 (0.69-1.29) \\

Results from GWAS in distinct populations, with the two most recent GWAS used for NHW. SNPs are presented for loci that have been 1) significantly associated with risk of AD in at least one population, and 2) have been tested in at least one other population, for comparison. Loci are named according to the reported closest gene. We have condensed the list of SNPs reported near the same gene in GWAS by using LDproxy (defining LD as R2>0.7). If there were multiple ORs for the same population (and either all or none reached GWS) then we present the OR from the study reporting the smallest p-value. These differences may be attributable to population-specific LD structures.

Studies used for ORs in table: A=22, B= OR and 95%CI calculated using beta and SE from 24 summary statistics: OR=exp(beta) and 95%CI= exp(beta+/- (SE*1.96)), C=43, D=57, E=44, F=37, G=48, H=58, I=42, J=53, K= In a Caribbean Hispanic LOAD GWAS, there are reports of associations (not reaching GWS) for rs881146 near CLU, with no association observed with rs11136000, rs17159904 near PICALM, and rs7561528 near BIN1, however, only the p-value is provided and so there is no OR added to table 1 59. Using the Wald test (if

\[
\frac{(\text{OR}_{\text{study}} - \text{OR}_{\text{comparison}})^2}{\text{SE}_{\text{study}}^2} > 1.96, \ p < 0.05
\]

There are no statistically significant differences when comparing ORs for NHWs to ORs for SNPs near the same gene in other populations. b=beta, n=sample size, SE= standard error.

* = p value for OR did not reach genome-wide significance (5x10^-8).

OR=odds ratio, 95%CI= 95% confidence interval

**Discovery of new AD risk variants in understudied populations**

We performed a literature search to identify SNPs reaching GWS for association with AD in understudied populations (Table 2) and explored if these have been replicated in any subsequent studies. Since the original reports of these five associations, four of these have no reports of follow-up, highlighting a need to replicate these studies. A single study identified a 665kb duplication spanning CACNA2D3 in post-mortem diagnosed LOAD from the Brain Bank of the Brazilian Aging Brain Study Group 60. Although this is not a confirmatory report, it is nonetheless interesting that a rare structural change in a post-mortem case overlapped a gene previously found to be associated with the same disease. There was also one report of statistically significant overexpression of Ccna2d3 in the hypothalamus of aggressive male rats compared to domesticated rats 61. It would be interesting to study such changes in carriers of the risk SNP at this locus since some behavioral changes have also been reported in AD patients.

Prior to the IGAP GWAS by Lambert et al., evidence for association at the SORL1 locus had been obtained in a Japanese case-control study and subsequently replicated in a combined Japanese, Korean and Caucasian cohort 58. A protective effect seems to be present in other populations as well (Table 1), with the exception of AAs where, so far, there is no evidence of association. A study in a Caribbean Hispanic familial and sporadic LOAD cohort, found 17 exonic variants significantly associated with AD and 3 shown to segregate with disease in families under a dominant model 62.

An interesting understudied population is the Wadi Ara, where there is a high prevalence of AD, low frequency of APOE E4 and high degrees of consanguinity. In this population, Sherva et al. performed a GWAS and homozygosity mapping to
identify new genes and risk loci for AD. Although they failed to find any significant SNPs in both the standard GWAS and the GWAS utilizing homozygous regions, they identified genes, such as APBA1 or AGER, with AD-related biological functions, that were located within stretches of homozygosity nominally associated with AD. The lack of significant results likely stems from the fact that this was a study conducted in a small cohort of samples (124 cases and 142 controls). Focusing on the homozygous regions is an interesting approach to studying populations with high levels of consanguinity.

### Table 2. Table of novel SNPs that were initially identified by reaching genome-wide significance in GWAS performed in understudied populations

<table>
<thead>
<tr>
<th>CHR</th>
<th>SNP-effect allele</th>
<th>Nearest gene</th>
<th>Population(s)</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>rs7431592-A</td>
<td>CACNA2D3</td>
<td>Caribbean Hispanics using model A (logistic)</td>
<td>77</td>
</tr>
<tr>
<td>5</td>
<td>rs75005042-A</td>
<td>FBXL7</td>
<td>Caribbean Hispanics using model A (logistic)</td>
<td>71</td>
</tr>
<tr>
<td>7</td>
<td>rs112404845-T</td>
<td>COBL</td>
<td>AA- not GWAS with logistic model but GWAS with liability model with APOE E4 and ABCA7 rs115550680 as covariates</td>
<td>72</td>
</tr>
<tr>
<td>13</td>
<td>rs16961023-G</td>
<td>SLC10A2</td>
<td>AA- not GWAS with logistic model but GWAS with liability model with APOE E4 and ABCA7 rs115550680 as covariates</td>
<td>72</td>
</tr>
<tr>
<td>19</td>
<td>rs115553053-T</td>
<td>HMHA1</td>
<td>AA</td>
<td>83</td>
</tr>
</tbody>
</table>

Since these associations were reported, there have been no further reports of associations between AD and FBXL7, COBL, SLC10A2 or HMHA1.

GWAS mostly identify variants which convey small alterations in risk, whereas familial studies have the power to identify rare, high effect variants. The homozygous TREM2 variants p.Gln33X, p.Thr66Met and p.Tyr38Cys were first identified associated with dementia in a report of 3 separate Turkish FTD-like dementia families. These mutations, when homozygous, were previously known to cause polycystic lipomembranous osteodysplasia with sclerosis leukenoencephalopathy (PLOSL), also known as Nasu Hakola Disease (NHD). The Turkish cases, however, displayed no apparent bone involvement in their phenotype with no history of joint pain or bone cysts. Since this initial finding in FTD-like families, Guerreiro et al., demonstrated that the heterozygous TREM2 p.Arg47His (rs75932628) is significantly associated with AD - a result that was found independently in the Icelandic population and has since been widely replicated, with significant associations reported for Spanish and French populations. Conversely, there are also studies reporting no significant association between rs75932628 and AD in Japanese, African American, Chinese populations, and Iranian populations, suggesting a population specific effect. In some populations not only is there no association, but also the p.Arg47His locus seems to be monomorphic, as is the case for the East Asian population in the latest version of gnomAD. Other variants in the gene have been identified in specific populations, such as the p.Gly55Arg variant reported in an Iranian cohort, and the p.Ala130Val in a Han Chinese LOAD patient. The noncoding variant rs7748513 is in LD with p.Arg47His and was reported to be associated with increased risk of AD in AAs. In addition to p.Arg47His, the p.Leu211Pro has also been shown to be associated with AD in AAs (p=0.01).

Two rare variants in AKAP9 were initially reported as nominally associated with AD in AAs. These two variants were also identified in individual Caribbean Hispanic LOAD cases. One of these two variants, the p.Arg434Trp, was reported in affected individuals from two large Caribbean Hispanic LOAD families. It is important to note that segregation was not shown for this variant, with absence in some affected individuals and presence in potentially presymptomatic individuals who were younger than the usual AAO of other family members. There was one exception of a single family member aged 78 who was unaffected but identified as a heterozygous carrier. Taken together this data argues against a fully penetrant mode for AKAP9 mutations in this Caribbean Hispanic family. Moreover, 4 other AKAP9 variants were reported in Caribbean Hispanic families, with 3 of them present in the same family. Two different AKAP9 variants have subsequently been reported in LOAD families of European ancestry, although segregation was not shown for either of them.

### Table 3. Variants in AKAP9 reported in different populations

<table>
<thead>
<tr>
<th>Variant</th>
<th>Amino acid</th>
<th>Population(s)</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs144662445</td>
<td>p.Arg434Trp</td>
<td>Caribbean Hispanic</td>
<td>82</td>
</tr>
<tr>
<td>rs1499799685</td>
<td>p.Ile1754Met</td>
<td>AA, Caribbean Hispanic</td>
<td>77,81</td>
</tr>
<tr>
<td>rs144868841*</td>
<td>p.Glu170Asp</td>
<td>Caribbean Hispanic</td>
<td>72</td>
</tr>
<tr>
<td>rs773608420</td>
<td>p.Arg434Trp</td>
<td>Caribbean Hispanic</td>
<td>72</td>
</tr>
<tr>
<td>chr7:91706306A/C*</td>
<td>p.Glu2250Asp</td>
<td>Caribbean Hispanic</td>
<td>72</td>
</tr>
<tr>
<td>rs144054367</td>
<td>p.Ile3558Met</td>
<td>Caribbean Hispanic</td>
<td>72</td>
</tr>
<tr>
<td>rs34301758*</td>
<td>p.Ala130Val</td>
<td>Caribbean Hispanic</td>
<td>72</td>
</tr>
<tr>
<td>rs200291548</td>
<td>p.Glu211Pro</td>
<td>European ancestry</td>
<td>72</td>
</tr>
<tr>
<td>rs146797353</td>
<td>p.Arg2880ln</td>
<td>European ancestry</td>
<td>72</td>
</tr>
</tbody>
</table>

*variants present in the same family.
Association of CASP7 with AD was first reported in a Caribbean Hispanic haplotype association study. Since this report, a loss-of-function variant (rs10553596) has been reported to reduce the risk of AD in APOE E4 homozygotes. This haplotype association study also reported significant association between LRP1B, TNFRSF1A, CDH1, and TG, with AD susceptibility in Caribbean Hispanic individuals. Finally, the CASP7 rs116437863 variant has been significantly associated with familial LOAD in individuals of European ancestry.

NOTCH3 variants have been associated with AD risk relatively recently and thus the impact of such variants is still not entirely clear. The NOTCH3:p.Arg1231Cys (rs201680145-A) mutation was first reported in one Caucasian patient with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). There have since been several reports of this mutation in CADASIL patients from central Italy, in one Russian CADASIL patient (a compound heterozygote with NOTCH3:p.Phe984Cys) and in a Turkish AD case. This variant is not reported in unrelated Chinese cases diagnosed with CADASIL. Since the report linking NOTCH3 mutations with AD, there has been growing evidence supporting this association. Following exome sequencing, a missense NOTCH3 variant (rs149307620, p.Ala284Thr) was reported in 10 AD cases (confirmed in 8), and not present in controls of European ancestry. Screening of WGS from the ADSP and ADNI datasets revealed this variant in one AD case, one MCI case and no controls. Moreover, two half-first cousins from a Utah high-risk pedigree both had rare missense variants in NOTCH3 which were not identified in the WGS samples from the ADSP and ADNI datasets. A study on the Han Chinese population reported the NOTCH3:p.Glu585Ala in 1 probable AD case (out of 210 AD cases) with early onset familial AD, which was absent from 160 population matched controls. Despite these results, studies in more populations and in larger sample sizes are required to fully establish the role of NOTCH3 variants in AD.

In summary, several variants and genes were initially identified and associated with AD in understudied populations that were later found to also have an effect in NHW individuals. This highlights the importance of performing family and cohort studies in diverse populations.

Discussion

The human reference genome is not representative of an average genome for all ethnicities, instead it is largely representative of NHW ancestry only. As our understanding of the genetics of human disease continues to evolve, this creates important limitations. It is also possible that regions encompassing damaging variants in some populations are not mapped in the current reference genome and thus will not be detected. Efforts have been made to create ethnicity-specific reference genomes and there is some interest in designing a pan-genome to account for all genetic variability. Recent work to create a pan-genome of African individuals highlighted that there is over 296.5Mb of DNA that is not accounted for in the current human genome reference.

There are disparities in gene variants associated with AD between populations, both from an effect size as well as direction of effect perspectives. These may be due to early human migration out of Africa and subsequent founder effects. In AD, as in all other complex diseases, substantially more samples of NHW ancestry are used for initial discovery in genetic studies for all diseases. Interestingly, with regards to populations used for replication studies, samples of Asian ancestry are currently the most commonly used after NHWs. The smaller sample sizes of AD cases obtained for other populations compared to NHWs, may be related to stigmatization of AD in some cultures, but also to funding availability for large-scale genetic research in those populations. However, it was recently shown that between 1990 and 2016 there has been an increase in both prevalence and burden of dementias in Eastern Mediterranean region countries, which may be due to a range of factors, such as an aging population or improved diagnostic methodologies. Based both on key past discoveries, and the potential for future findings, funding to facilitate the study of understudied populations is imperative. The immediate need to address ethnic and racial disparities in AD and related dementias has been the focus of a recent white paper, which developed a series of recommendations for future strategies. These included targeted study recruitment and retention of diverse ethnoracial populations, generalization of instruments and analytic methods across research groups, ensuring that ethnoracial sub-group data is reported, creation of methods to reduce impact of small sample size on...
observations, and development of statistical models of risk and protective factors relevant to ethnoracial groups, to better refine prevalence and incidence.  

Data from the UK Biobank, which is largely European-based, has been used in AD GWAS by taking advantage of proximal AD status, where an individual is considered as AD-by-proxy if they report AD in one of their parents, while individuals with parents without history of AD are considered by-proxy-controls. This is an approach that could be used to increase the sample sizes of understudied populations and thus the power for detecting associations. As detailed above, it is critically important to have a better understanding of the allele frequencies across populations, something that population variant databases such as ExAC and gnomAD have enabled us to do, to a certain degree, for some populations. For Middle Eastern populations, at a smaller scale and with no information on family history, one available resource is the Greater Middle East Variome (WES data on 1,111 unrelated subjects from populations including Northwest and Northeast Africa, the Turkish Peninsula, the Syrian Desert, the Arabian Peninsula, and Persia and Pakistan). Other population-specific databases include the GenomeAsia 100K Project, the Han Chinese genome database, the Japanese Human Genetic Variation Database and the Genome of the Netherlands. Additionally, studies on populations with large genetic bottlenecks, such as Finland, where there is increased frequency of extremely rare alleles, can increase the power for finding associations, without needing to drastically increase sample size.

Large cohorts with the same mutation, such as the Colombian, have demonstrated the power to study genetic disease modifiers, clinical biomarkers and therapeutics with the potential to translate findings to other populations. Related to the clinical setting, polygenic risk scores take into account SNPs across the genome that were associated with modulating risk for disease. The best predictors of risk are derived from the largest GWAS as these will be the best powered studies to identify risk loci and estimate their effect size. Currently, the largest GWAS are on NHWs, which raises the question of how valid these PRSs are for prediction of AD risk in other populations. If greater diversity is not prioritized in genetic studies, current PRSs may be irrelevant for the majority of the world’s populations and may exacerbate health disparities.

The vast majority of genetic findings in complex disease in general and AD in particular have been made in broadly NHW populations. We have highlighted here how important findings from other populations have been reported over the years and how they have improved our understanding of the genetic bases of this disease. A shift in funding strategies and a broader collaborative mindset is required to allow us to create the next step-change that is needed to move the field to a complete understanding of the genetic architecture of AD across populations.

Author Contributions and Notes
We contributed equally to the preparation and writing of the manuscript, and we all approved the final version.

Declaration of Interests
The authors declare no conflict of interest.

Acknowledgements
We thank the Van Andel Institute Bioinformatics and Biostatistics Core, especially Emily Wolfrum and Zach Madaj, for their statistical expertise. Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Number R01AG067426. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
References


37. Logue MW, Schu M, Vardarajan BN, et al. A comprehensive genetic association study of Alzheimer disease in...


